Rectify Pharmaceuticals Appoints Bharat Reddy as Chief Business Officer
2024年7月15日 - 9:00PM
Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company
developing small molecule disease-modifying therapeutics that
restore and enhance ABC transporter function, today announced the
appointment of Bharat Reddy, Ph.D., as Chief Business Officer. Mr.
Reddy brings over 10 years of business development and strategy
expertise in the biopharmaceutical industry and will lead business
development activities for the company.
“I am delighted to welcome Bharat to the Rectify team,” said
Rajesh Devraj, Ph.D., President and Chief Executive Officer of
Rectify. “His proven track record of advancing partnerships in the
biopharma industry will be critical as we build the
industry-leading ABC transporter therapeutics company and advance
our business goals.”
Dr. Reddy added, “Rectify is the first company to tap into the
ABC transporter protein superfamily, and our platform is uniquely
positioned to develop disease-modifying therapies that restore and
enhance ABC transporter function. I look forward to working with
the executive team and the Board on strategic partnership
opportunities to advance the company’s development candidates and
bring hope to patients in need.”
Dr. Reddy is an accomplished biopharma leader with deep
experience in corporate affairs, strategic partnerships and
collaborations, and academia. He most recently served as Vice
President, Strategy and Business Development, at Kelonia
Therapeutics where he designed and implemented a business strategy
plan and fostered a multi-year collaboration and licensing
agreement with Astellas Pharmaceuticals. Prior to this role, Dr.
Reddy served as Head of Business Development at Catamaran Bio
following his tenure as entrepreneur in residence at SV Health
Investors where he played an integral role in Catamaran’s launch.
Prior to Catamaran Bio, he served as Director, Business
Development, at bluebird bio. He started his career as a Life
Sciences strategy consultant with ClearView Healthcare Partners.
Dr. Reddy holds a B.A. in Biology and Anthropology from Bowdoin
College and a Ph.D. from the Department of Biological Sciences at
Columbia University.
About Rectify Pharmaceuticals, Inc.
(“Rectify”)
Rectify is a development stage biotechnology company developing
Positive Functional Modulators (PFMs), disease-modifying
therapeutics that restore and enhance ABC transporter function to
address the underlying cause of serious ABC transporter mediated
diseases. Rectify is the first company to directly address the
untapped therapeutic potential of the ATP-binding cassette (ABC)
transporter target class, a 48-member superfamily of membrane-bound
proteins that actively export a diverse range of substrates across
lipid membranes. The Company’s breakthrough product platform
enables efficient and rapid discovery of first-in-class small
molecule therapies with potential to address ABC transporter
dysfunction in rare and common liver, biliary, eye and CNS
diseases. Rectify was founded and seeded by Atlas Venture who
co-led the $100M Series A round with Omega Funds and were joined by
Forbion and Longwood Fund.
For more information, please visit www.rectifypharma.com or
follow us on X and LinkedIn.
Contact
MediaMichael RubensteinLifeSci Communications+1
646-386-1613mrubenstein@lifescicomms.com